Viking Therapeutics, Inc.

NasdaqCM:VKTX 株式レポート

時価総額:US$6.0b

Viking Therapeutics 過去の業績

過去 基準チェック /06

Viking Therapeuticsの収益は年平均-25.6%で減少しているが、Biotechs業界はgrowingで19.3%年平均の収益となった。

主要情報

-25.6%

収益成長率

-18.3%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率n/a
株主資本利益率-10.9%
ネット・マージンn/a
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

収支内訳

Viking Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:VKTX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 240-994391
30 Jun 240-973887
31 Mar 240-943777
31 Dec 230-863764
30 Sep 230-813259
30 Jun 230-742853
31 Mar 230-722253
31 Dec 220-691654
30 Sep 220-621548
30 Jun 220-591347
31 Mar 220-571246
31 Dec 210-551145
30 Sep 210-541044
30 Jun 210-501041
31 Mar 210-441035
31 Dec 200-391132
30 Sep 200-361129
30 Jun 200-321027
31 Mar 200-311027
31 Dec 190-26924
30 Sep 190-24922
30 Jun 190-24823
31 Mar 190-23820
31 Dec 180-22719
30 Sep 180-21717
30 Jun 180-20615
31 Mar 180-19613
31 Dec 170-21514
30 Sep 170-20513
30 Jun 170-18512
31 Mar 170-16511
31 Dec 160-1559
30 Sep 160-16510
30 Jun 160-17610
31 Mar 160-2169
31 Dec 150-2357
30 Sep 150-1744
30 Jun 150-1222
31 Mar 150-27122
31 Dec 140-22122
30 Sep 140-23122
30 Jun 140-23121
31 Mar 140000

質の高い収益: VKTXは現在利益が出ていません。

利益率の向上: VKTXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: VKTXは利益が出ておらず、過去 5 年間で損失は年間25.6%の割合で増加しています。

成長の加速: VKTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: VKTXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: VKTXは現在利益が出ていないため、自己資本利益率 ( -10.88% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘